Fibromyalgia and the endocannabinoid system John M. McPartland in Fibromyalgia syndrome : A practitioner’s guide to treatment, chapter 11, 2010, 263-277. Doi : 10.1016/B978-0-443-06936-9.00011-1 CHAPTER CONTENTS Introduction . . . . . . . . . . . . . . . 263 Cannabis and cannabinoid receptors . . 264 Endocannabinoids and their enzymes . 266 Nociception and pain . . . . . . . . . . 266 Around the edges of fibromyalgia . . . . 269 Enhancing the eCB system . . . . . . . 270 Other approaches . . . . . . . . . . . . 272 Conclusions . . . . [...]
Lire la suiteThe effects of psilocybin on cognitive and emotional functions in healthy participants : Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation James J Rucker, Lindsey Marwood, Riikka-Liisa J Ajantaival, Catherine Bird, Hans Eriksson, John Harrison, Molly Lennard-Jones, Sunil Mistry, Francesco Saldarini, Susan Stansfield, Sara J Tai, Sam Williams, Neil Weston, Ekaterina Malievskaia and Allan H Young Abstract Background : Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin’s effects on cognitive function have not been widely or systematically studied. Aim : The aim of this study was to [...]
Lire la suiteMedical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt BMJ Paediatrics Open, 2021, 5, e001234. doi : 10.1136/bmjpo-2021-001234 ABSTRACT Objectives : To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children. Setting : This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children [...]
Lire la suiteWhole-plant Cannabis Linked to Large Reduction in Seizures Kelli Whitlock Burton Medscape - Dec 29, 2021. https://www.medscape.com/viewarticle/965756 Whole-plant cannabis is linked to a significant reduction in seizures in children with severe treatment-resistant epilepsy, early research suggests. In a small case series, children with severe treatment-resistant epilepsy treated with a range of whole-plant extract cannabis-based medical products (CBMPs) reported an 86% reduction in monthly seizures. All participants had no improvement with traditional antiepileptic drugs (AEDs). The study adds to a small but growing body of research investigating whole-plant cannabis medicines containing tetrahydrocannabinol (THC) in pediatric epilepsies. Rayyan Raja Zafar "Although we have previously noted the superior efficacy of whole-plant medical cannabis is a previous [...]
Lire la suiteEpidiolex Plus THC May Lower Seizures in Pediatric Epilepsy Randy Dotinga Medscape.com - Oct 14, 2021. https://www.medscape.com/viewarticle/960842 Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high in larger quantities, researchers reported. "THC can contribute to seizure control and mitigation some of the side effects of CBD," said study coauthor and Austin, Tex., child neurologist Karen Keough, MD, in an interview. Keough and colleagues presented their findings at the 50th annual meeting of the Child Neurology Society. In a landmark move, the Food and [...]
Lire la suiteLong-Term Efficacy for Epidiolex in Resistant Epilepsy Pauline Anderson Medscape - Dec 17, 2018. https://www.medscape.com/viewarticle/906653 NEW ORLEANS — Results of open-label extension trials show the recently approved drug Epidiolex (GW Pharmaceuticals), a purified formulation of cannabidiol (CBD), is safe and effective beyond a year in patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome, two rare and resistant epilepsy types. "We now have long-term data to say that it still works; the efficacy is not going to drop off, and more importantly, it's still going to be safe and you're not going to learn anything new down the road," study author Anup D. Patel, MD, Section Chief of Pediatric Neurology, [...]
Lire la suitePsychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020 After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction. Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]
Lire la suiteRediscovering Psilocybin as an Antidepressive Treatment Strategy Rene Zeiss, Maximilian Gahr and Heiko Graf Pharmaceuticals, 2021, 14, 985, 1-14. doi : 10.3390/ph14100985 Abstract : There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we provide an overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks [...]
Lire la suiteCannabidiol modulation of oxidative stress and signalling Sonia R. Pereira, Becky Hackett, David N. O’Driscoll, Melody Cui Sun and Eric J. Downer Neuronal Signaling, 2021, 5, NS20200080 doi : 10.1042/NS20200080 Cannabidiol (CBD), one of the primary non-euphoric components in the Cannabis sativa L. plant, has undergone clinical development over the last number of years as a therapeutic for patients with Lennox-Gastaut syndrome and Dravet syndromes. This phytocannabinoid demonstrates functional and pharmacological diversity, and research data indicate that CBD is a comparable antioxidant to common antioxidants. This review gathers the latest knowledge regarding the impact of CBD on oxidative signalling, with focus on the proclivity [...]
Lire la suiteEDITORIAL : Cannabinoids in psychiatry : they are here to stay Julia Jiyeon Woo, Emma van Reekum, Sagnik Bhattacharyya and Zainab Samaan The British Journal of Psychiatry, 2022, 1-3. doi : 10.1192/bjp.2021.216 Summary Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids. Keywords : Cannabis; drug interactions and side-effects; drugs of dependence disorders; marijuana; education and training. Vignette A young man sits in his psychiatrist’s office. After [...]
Lire la suite